Compare NATH & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATH | TECX |
|---|---|---|
| Founded | 1916 | 2019 |
| Country | United States | United States |
| Employees | 131 | 51 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 393.0M |
| IPO Year | 1996 | N/A |
| Metric | NATH | TECX |
|---|---|---|
| Price | $100.65 | $31.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $80.40 |
| AVG Volume (30 Days) | 21.0K | ★ 306.4K |
| Earning Date | 02-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 22.29 | N/A |
| EPS | ★ 4.17 | N/A |
| Revenue | ★ $104,201,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.13 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $88.00 | $13.70 |
| 52 Week High | $118.32 | $35.99 |
| Indicator | NATH | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 57.49 |
| Support Level | $100.25 | $16.83 |
| Resistance Level | $101.86 | $35.99 |
| Average True Range (ATR) | 0.45 | 2.57 |
| MACD | -0.07 | -0.52 |
| Stochastic Oscillator | 60.00 | 38.91 |
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.